Literature DB >> 17525362

Thrombotic thrombocytopenic purpura in humans and mice.

Karl C Desch1, David G Motto.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a disorder of blood coagulation that presents classically with the pentad of fever, thrombocytopenia, microangiopathic hemolytic anemia, renal dysfunction and mental status changes. However, the clinical presentation can be quite variable making the diagnosis difficult in many cases. "Hyaline" microthrombi composed primarily of platelets and Von Willebrand Factor (VWF) are found in the small vessels of affected organs and represent the pathological hallmark of the disease. The accompanying tissue ischemia is thought to explain the clinical TTP signs and symptoms. Pathogenesis of TTP has been linked to dysfunction of ADAMTS13, a metalloprotease whose only known substrate is VWF. Interestingly, further investigation into the natural history of TTP has demonstrated that ADAMTS13 deficiency likely is necessary, but not sufficient for the development of this disease, suggesting that additional genetic and/or environmental factors are required for TTP pathogenesis. Recently, a mouse model of TTP was established that recapitulates many of the key clinical features of this disease, including the requirement for further genetic and environmental factors in addition to ADAMTS13 deficiency. Therefore, in addition to being useful for the direct study of disease pathophysiology in vivo, this mouse model may also play a key role in elucidating some of the important environmental and genetic contributors to disease pathogenesis. Here we will review TTP in humans, and then discuss recent information gained from the analysis of ADAMTS13-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525362     DOI: 10.1161/ATVBAHA.107.145797

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  15 in total

1.  Retrograde Shiga toxin trafficking is regulated by ARHGAP21 and Cdc42.

Authors:  Heidi Hehnly; Katrina Marie Longhini; Ji-Long Chen; Mark Stamnes
Journal:  Mol Biol Cell       Date:  2009-08-19       Impact factor: 4.138

Review 2.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

3.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.

Authors:  Eric M Ostertag; Khalil Bdeir; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; Lenka Yunk; Vincent M Hayes; David G Motto; Mortimer Poncz; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

4.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.

Authors:  Eric M Ostertag; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

5.  Degradation of platelet-von Willebrand factor complexes by plasmin: an alternative/backup mechanism to ADAMTS13.

Authors:  Anil K Chauhan
Journal:  Circulation       Date:  2014-01-21       Impact factor: 29.690

Review 6.  Endothelial cells and thrombotic microangiopathy.

Authors:  David Motto
Journal:  Semin Nephrol       Date:  2012-03       Impact factor: 5.299

7.  von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice.

Authors:  P M Jacobi; S Kanaji; D Jakab; A L Gehrand; J M Johnsen; S L Haberichter
Journal:  J Thromb Haemost       Date:  2018-01-24       Impact factor: 5.824

8.  Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.

Authors:  Reheman Adili; Michael Holinstat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-25       Impact factor: 8.311

9.  The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation.

Authors:  Fumiaki Banno; Anil K Chauhan; Koichi Kokame; Jin Yang; Shigeki Miyata; Denisa D Wagner; Toshiyuki Miyata
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

10.  ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: a clue for disease mechanism?

Authors:  M C Kappers-Klunne; J G van Asten; H H van Vliet
Journal:  Ann Hematol       Date:  2009-02-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.